EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

POTENSI SEL T MOBIL HER2 SPESIFIK MODIFIKASI CRISPR / CAS9 PD-1 / PD-L1 PEMBLOKIRAN SEBAGAI INOVASI TERAPI UVEAL MELANOMA

Muhammad AH Khoiruddin, Yusi Windya Febriyanti, Nafia Amalia

Al-Iqra Medical Journal : Jurnal Berkala Ilmiah Kedokteran · 2019

DOI: 10.26618/aimj.v3i1.2745 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Al-Iqra Medical Journal : Jurnal Berkala Ilmiah Kedokteran, 2019. Verfasst von Muhammad AH Khoiruddin und 2 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Uveal Melanoma (UM) is the primary intraocular tumor most commonly found in adults. The combination of therapy, Brachytherapy, surgery, Tranpupillary Thermal Therapy (TTT), Proton Beam Theraphy has not produced satisfactory results. The discovery of HER2 receptors expressed by UM cells can be used as a specific antigen target for the treatment of CAR T-celss. However, the effectiveness of CAR T-cell immunotherapy in tumors results in immunosuppressive T cells caused by an increase in Programmed cell Death Ligand-1 (PD-L1). This literature review demonstrates the success of HER2-specific CART T Cells as UM therapeutic efforts capable of eliminating tumor cells. In addition, CRSPR / Cas9 PD-1 / PD-L1-blocking modified HER2-specific CAR T cells can be a gene innovation in UM sufferers. Further clinical trials are needed to prove the effectiveness of CRISPR / Cas9 PD-1 / PD-L1-Blocking modified HER2-specific CAR T Cells in the treatment of UM patients.Keywords: Uveal melanoma, CAR T cell, reseptor HER

Zitieren

APA

Khoiruddin, M. A., Febriyanti, Y. W., & Amalia, N. (2019). POTENSI SEL T MOBIL HER2 SPESIFIK MODIFIKASI CRISPR / CAS9 PD-1 / PD-L1 PEMBLOKIRAN SEBAGAI INOVASI TERAPI UVEAL MELANOMA. Al-Iqra Medical Journal : Jurnal Berkala Ilmiah Kedokteran. https://doi.org/10.26618/aimj.v3i1.2745

Vancouver

Khoiruddin MA, Febriyanti YW, Amalia N. POTENSI SEL T MOBIL HER2 SPESIFIK MODIFIKASI CRISPR / CAS9 PD-1 / PD-L1 PEMBLOKIRAN SEBAGAI INOVASI TERAPI UVEAL MELANOMA. Al-Iqra Medical Journal : Jurnal Berkala Ilmiah Kedokteran. 2019. doi:10.26618/aimj.v3i1.2745

BibTeX
@article{Khoiruddin2019,
  author = {Khoiruddin, Muhammad AH and Febriyanti, Yusi Windya and Amalia, Nafia},
  title = {POTENSI SEL T MOBIL HER2 SPESIFIK MODIFIKASI CRISPR / CAS9 PD-1 / PD-L1 PEMBLOKIRAN SEBAGAI INOVASI TERAPI UVEAL MELANOMA},
  journal = {Al-Iqra Medical Journal : Jurnal Berkala Ilmiah Kedokteran},
  year = {2019},
  doi = {10.26618/aimj.v3i1.2745}
}
Kostenlos starten →